NCT01092728View on ClinicalTrials.gov

Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma

PHASE2TerminatedINTERVENTIONAL

Enrollment

19

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions

Melanoma

Interventions

DRUG

Dasatinib

100 mg daily.

PROCEDURE

Surgical Resection

Complete surgical resection of tumor(s).

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER